Barcelona, 15 March 2021 – Peptomyc is very proud to announce that today the company has reached another major milestone obtaining the approval from the Spanish authorities (AEMPS) to initiate the First in Human Phase I/II trial with its first compound OMO-103 in patients with advanced solid tumors. Peptomyc will soon start treating the first patients with this disruptive Myc inhibitor in selected clinical sites in Barcelona and Madrid. The company could achieve this key milestone thanks to an outstanding team, great collaborators and consultants. 

The Chief Medical Officer of Peptomyc, Manuela Niewel, MD, PhD, comments: “Now we will be able to translate the good preclinical results into hopefully great benefit for the patients”. 


Download PDF:
20210312- Communication-CTA Approval-FV


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 872212